Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

Oncotarget

Volumn 7, Issue 9, 2016, Pages 9707-9716

  Schwaederle, Maria ^a   Husain, Hatim ^a   Fanta, Paul T ^a   Piccioni, David E ^a   Kesari, Santosh ^a   Schwab, Richard B ^a   Banks, Kimberly C ^b   Lanman, Richard B ^b   Talasaz, AmirAli ^b   Parker, Barbara A ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Guardant Health   (United States)

Author keywords

Actionable alteration; Cancer; CtDNA; Liquid biopsy; Personalized therapy

Indexed keywords

CELL FREE DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NOTCH1 RECEPTOR; PROTEIN P53; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; MET PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CIRCULATING TUMOR CELL; CONTROLLED STUDY; COPY NUMBER VARIATION; EGFR GENE; FEMALE; GENE MUTATION; GLIOBLASTOMA; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MET GENE; NOTCH1 GENE; PIK3CA GENE; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE; BIOPSY; BLOOD; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; NEOPLASM; PATHOLOGY; RETROSPECTIVE STUDY; TUMOR EMBOLISM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, NOTCH1; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84961636991     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7110     Document Type: Article

References (38)

1. Tsimberidou A-M, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15;18:6373-83.
2. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. The Oncologist. 2014 Jun;19:631-6.
3. Kris MG, Johnson BE, Berry LD, et al. USing multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21;311:1998-2006.
4. Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010 Nov 20;28:4877-83.
5. Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and coamplification network. Oncotarget. 2015 Feb 20;6:3033-42. doi: 10.18632/oncotarget.2848.
6. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Aug 24;JCO.2015.61.5997.
7. Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov;107.
8. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4;304:1497-500.
9. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med. 2011;364:2507-16.
10. Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med. 2011;365:1448-50.
11. Barbany G, Höglund M, Simonsson B. Complete Molecular Remission in Chronic Myelogenous Leukemia after Imatinib Therapy. N Engl J Med. 2002;347:539-40.
12. Boros LG, Lee W-NP, Cascante M. Imatinib and Chronic-Phase Leukemias. N Engl J Med. 2002;347:67-8.
13. De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard F-C, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-ofprinciple. Ann Oncol. 2014 Sep;25:1729-35.
14. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N Engl J Med. 2012;366:883-92.
15. Ng CKY, Pemberton HN, Reis-Filho JS. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther. 2012 Aug;12:1021-32.
16. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005 Mar;2:e73.
17. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. 2010 Sep;7:493-507.
18. Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in nonsmall cell lung cancer. Oncotarget. 2015; 6:6029-39. doi: 10.18632/oncotarget.3472.
19. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008 Sep;14:985-90.
20. Hyman DM, Diamond EL, Vibat CRT, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, et al. Prospective blinded study of BRAFV600E mutation detection in cellfree DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015 Jan;5:64-71.
21. Janku F, Vibat CRT, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget. 2014; 5:3607-10. doi: 10.18632/oncotarget.1964.
22. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, et al. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20;6:12809-21. doi: 10.18632/oncotarget.3373.
23. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. Oncotarget. 2013 May 1;4:705-14. doi: 10.18632/oncotarget.974.
24. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31;511:543-50.
25. Bean J, Brennan C, Shih J-Y, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang W-C, Yu C-J, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007 Dec 26;104:20932-7.
26. Chen H-J, Mok TS, Chen Z-H, Guo A-L, Zhang X-C, Su J, Wu Y-L. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res POR. 2009 Dec;15:651-8.
27. de Melo Gagliato D, Fontes Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, et al. Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. Clin Breast Cancer. 2014 Dec;14:468-74.
28. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, et al. Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. The Oncologist. 2014 Jun 1;19:616-22.
29. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Mol Cancer Ther. 2015 Jun;14:1488-94.
30. Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. The Oncologist. 2014 May;19:453-8.
31. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, et al. Detection of Circulating Tumor DNA in Early-and Late-Stage Human Malignancies. Sci Transl Med. 2014 Feb 19;6:224ra24-224ra24.
32. ctDNA Is a Specific and Sensitive Biomarker in Multiple Human Cancers. Cancer Discov. 2014 Apr 1;4(4):OF8-OF8.
33. Pan W, Gu W, Nagpal S, Gephart MH, Quake SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015 Mar;61:514-22.
34. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience. 2014;1:614-23. doi: 10.18632/oncoscience.90.
35. Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013 Mar 28;368:1199-209.
36. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen C-T, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486:532-6.
37. Schwaederle M, Piccioni D, Kesari S, Hasain H, Patel S, Kurzrock R. Use of liquid biopsies in clinical oncology: the UCSD Moores Cancer Center experience in 168 patients with diverse malignancies.
38. Lokhandwala, T., Dann, R., Johnson, M., D'Souza, A. O. Medicare costs analysis indicates need for decreasing use of biopsies as diagnosis tool for lung cancer. [Abstract 3373]. Multidiscip Symp Thorac Oncol. 2014.